Results 161 to 170 of about 1,492,497 (311)

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Leisure time satisfaction as a predictor of life satisfaction among teachers. [PDF]

Front Psychol
Karadayi F, İyikal Çelebi A, Şenol H.
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Full scale test results

Demonstration on the performance of the retrofitted ship.
openaire   +1 more source

The translation and validation of the YouTube addiction scale in modern standard Arabic among emerging and young adults. [PDF]

Discov Ment Health
Jahrami H, Trabelsi K, Husain W, Ghazzawi H, Saif Z, Ammar A, Pakpour AH.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Full scale test doorlatende verharding: Dussen 23 okt 2013

, 2013
Beschrijving van de meetdag in Dussen, 23 okt 2013 met gemeente Werkendam en waterschap Rivierenland en diverse andere partijen. Het betreft een full scale test aan doorlatende verharding met een lavapakket aangelegd in 2006. Deze proef wordt herhaald na
Boogaard, Floris
core  

On the usefulness of Thompson´s test with a four-point scale after Achilles tendon rupture, a pilot study. [PDF]

BMC Musculoskelet Disord
Wetterteg AL, Riad J, Nordin P.
europepmc   +1 more source

Editorial: Large-Scale and Full-Scale Laboratory Test Methods for Examining Wind Effects on Buildings

Frontiers in Built Environment, 2018
Gregory A. Kopp
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source